kr91.80
1.13%
Stockholm, Oct 02, 05:29 pm CEST. Closed.
ISIN
SE0011205202
Symbol
VITR

Vitrolife Target price 2026 - Analyst rating & recommendation

Vitrolife Classifications & Recommendation

Buy
73%
Hold
27%

Vitrolife Price Target

Target Price kr132.60
Price kr91.80
Potential
Number of Estimates 8
8 Analysts have issued a price target Vitrolife 2027 . The average Vitrolife target price is kr132.60. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 8 Analysts recommend Vitrolife to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Vitrolife stock has an average upside potential 2027 of . Most analysts recommend the Vitrolife stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Billion kr 3.44 3.52
4.68% 2.44%
EBITDA Margin 24.04% 32.29%
17.84% 34.31%
Net Margin -145.70% 14.07%
1,125.00% 109.66%

8 Analysts have issued a sales forecast Vitrolife 2026 . The average Vitrolife sales estimate is

kr3.5b
unlock
. This is
3.92% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
kr3.7b 7.87%
unlock
, the lowest is
kr3.4b 0.86%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 kr3.4b 4.68%
2026
kr3.5b 2.44%
unlock
2027
kr3.8b 6.87%
unlock
2028
kr4.0b 7.01%
unlock
2032
kr5.3b 6.97%
unlock
2033
kr5.6b 5.99%
unlock

8 Analysts have issued an Vitrolife EBITDA forecast 2026. The average Vitrolife EBITDA estimate is

kr1.1b
unlock
. This is
28.88% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
kr1.2b 35.56%
unlock
, the lowest is
kr1.1b 22.65%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 kr827m 21.69%
2026
kr1.1b 37.61%
unlock
2027
kr1.2b 8.88%
unlock
2028
kr1.4b 9.36%
unlock

EBITDA Margin

2025 24.04% 17.84%
2026
32.29% 34.31%
unlock
2027
32.90% 1.89%
unlock
2028
33.62% 2.19%
unlock

7 Vitrolife Analysts have issued a net profit forecast 2026. The average Vitrolife net profit estimate is

kr496m
unlock
. This is
109.96% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
kr537m 110.79%
unlock
, the lowest is
kr451m 109.06%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 kr-5.0b 1,077.00%
2026
kr496m 109.89%
unlock
2027
kr603m 21.56%
unlock
2028
kr705m 17.00%
unlock

Net Margin

2025 -145.70% 1,125.00%
2026
14.07% 109.66%
unlock
2027
16.01% 13.79%
unlock
2028
17.50% 9.31%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share kr -37.01 3.66
1,076.52% 109.89%
P/E 25.07
EV/Sales 3.79

7 Analysts have issued a Vitrolife forecast for earnings per share. The average Vitrolife EPS is

kr3.66
unlock
. This is
109.95% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
kr3.97 110.79%
unlock
, the lowest is
kr3.33 109.05%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 kr-37.01 1,076.52%
2026
kr3.66 109.89%
unlock
2027
kr4.45 21.58%
unlock
2028
kr5.21 17.08%
unlock

P/E ratio

Current -2.50 106.50%
2026
25.07 1,104.45%
unlock
2027
20.62 17.75%
unlock
2028
17.63 14.50%
unlock

Based on analysts' sales estimates for 2026, the Vitrolife stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.94 24.38%
2026
3.79 3.82%
unlock
2027
3.55 6.43%
unlock
2028
3.31 6.55%
unlock
2032
2.53 6.52%
unlock
2033
2.39 5.65%
unlock

P/S ratio

Current 3.71 24.47%
2026
3.57 3.77%
unlock
2027
3.34 6.43%
unlock
2028
3.12 6.55%
unlock
2032
2.38 6.52%
unlock
2033
2.25 5.65%
unlock

Current Vitrolife Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
PARETO SECURITIES AS
Locked
➜
Locked
Locked Jul 20 2026
HANDELSBANKEN CAPITAL MARKETS
Locked
➜
Locked
Locked Jul 17 2026
DNB CARNEGIE
Locked
➜
Locked
Locked Jul 17 2026
HANDELSBANKEN CAPITAL MARKETS
Locked
➜
Locked
Locked Jul 08 2026
HANDELSBANKEN CAPITAL MARKETS
Locked
➜
Locked
Locked Jul 07 2026
DNB CARNEGIE
Locked
➜
Locked
Locked Jun 30 2026
PARETO SECURITIES AS
Locked
➜
Locked
Locked Jun 29 2026
Analyst Rating Date
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
Jul 20 2026
Locked
HANDELSBANKEN CAPITAL MARKETS:
Locked
➜
Locked
Jul 17 2026
Locked
DNB CARNEGIE:
Locked
➜
Locked
Jul 17 2026
Locked
HANDELSBANKEN CAPITAL MARKETS:
Locked
➜
Locked
Jul 08 2026
Locked
HANDELSBANKEN CAPITAL MARKETS:
Locked
➜
Locked
Jul 07 2026
Locked
DNB CARNEGIE:
Locked
➜
Locked
Jun 30 2026
Locked
PARETO SECURITIES AS:
Locked
➜
Locked
Jun 29 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today